Amylyx Pharmaceuticals Canada has entered into a Product Listing Agreement with British Columbia for the public reimbursement of ALBRIOZA, a drug used in the treatment of amyotrophic lateral sclerosis (ALS). British Columbia is the third province to provide public reimbursement for the drug. The decision ensures that British Columbians living with ALS who rely on public coverage can access timely treatment.